Journal
LEUKEMIA RESEARCH
Volume 36, Issue 9, Pages 1193-1199Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2012.04.007
Keywords
Acute Myeloid Leukemia (AML); Dendritic cell; TLR agonists
Categories
Funding
- Tehran University of Medical Sciences [8606-30-01-88]
- Hematology, Oncology and Bone Marrow Transplantation Research Center (Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran)
Ask authors/readers for more resources
Leukemic cells from AML patients can be differentiated to dendritic cells (DCs). Such DCs have potential for immunotherapy of patients. Blasts from 15 AML patients were differentiated into DCs and matured by different TLR agonists. We could generate AML-DCs from 73% of patients mostly with M4 or M5 subtypes. The DC recoveries ranged from 28% to 50%. The results showed that concomitant use of TLR4 and TLR7/8 agonists induced proficient DCs. Therefore, a combination of TLR4 and 7/8 agonists can be considered as an appropriate maturation cocktail for AML-DC production in order to use in the immunotherapy of AML patients. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available